However, it still remains to be determined if activation by EGF or somatic-activating mutations in the kinase domain of EGFR has any effect on the production of IL-6 or GP130 family of cytokines that can lead to the activated status of STAT3 in ovarian carcinomas. This evidence concerns the gene STAT3 and ovarian carcinoma.